LLY

1,065.38

+0.03%↑

JNJ

208.01

-1.23%↓

ABBV

224.28

-0.28%↓

UNH

331.13

+1.25%↑

AZN

90.81

+0.46%↑

LLY

1,065.38

+0.03%↑

JNJ

208.01

-1.23%↓

ABBV

224.28

-0.28%↓

UNH

331.13

+1.25%↑

AZN

90.81

+0.46%↑

LLY

1,065.38

+0.03%↑

JNJ

208.01

-1.23%↓

ABBV

224.28

-0.28%↓

UNH

331.13

+1.25%↑

AZN

90.81

+0.46%↑

LLY

1,065.38

+0.03%↑

JNJ

208.01

-1.23%↓

ABBV

224.28

-0.28%↓

UNH

331.13

+1.25%↑

AZN

90.81

+0.46%↑

LLY

1,065.38

+0.03%↑

JNJ

208.01

-1.23%↓

ABBV

224.28

-0.28%↓

UNH

331.13

+1.25%↑

AZN

90.81

+0.46%↑

Search

Simulations Plus Inc

Slēgts

SektorsVeselības aprūpe

18.53 -0.8

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

18.07

Max

18.81

Galvenie mērījumi

By Trading Economics

Ienākumi

67M

-681K

Pārdošana

-2.9M

17M

P/E

Sektora vidējais

48.528

76.798

EPS

-0.034

Dividenžu ienesīgums

0.48

Peļņas marža

-3.9

Darbinieki

212

EBITDA

327K

5.3M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+9.63% upside

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

0.48%

2.37%

Nākamie ieņēmumi

2026. g. 8. janv.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

47M

391M

Iepriekšējā atvēršanas cena

19.33

Iepriekšējā slēgšanas cena

18.53

Ziņu noskaņojums

By Acuity

58%

42%

316 / 374 Rangs Healthcare

Simulations Plus Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 18. dec. 23:54 UTC

Karstas akcijas

Stocks to Watch: Nike, Cassava Sciences, KB Home

2025. g. 18. dec. 23:51 UTC

Peļņas

Nike Sales Tick Up in 2Q; China Weakness Persists -- Update

2025. g. 18. dec. 23:39 UTC

Galvenie tirgus virzītāji

Cassava Sciences Shares Fall After FDA Places Hold on Epilepsy Drug Trial

2025. g. 18. dec. 22:57 UTC

Iegādes, apvienošanās, pārņemšana

TikTok Signs Agreement for Sale of U.S. Unit, Axios Reports, Citing a Memo

2025. g. 18. dec. 21:40 UTC

Peļņas

Nike Sales Tick Up, But China Weakness Persists

2025. g. 18. dec. 23:45 UTC

Tirgus saruna

Gold Steady, Supported by Fed Rate-Cut Prospects -- Market Talk

2025. g. 18. dec. 23:37 UTC

Tirgus saruna
Peļņas

Nike 2Q Results Fail to Convince Investors of Recovery -- Market Talk

2025. g. 18. dec. 23:36 UTC

Tirgus saruna

Nikkei May Rise, Tracking Wall Street's Rally -- Market Talk

2025. g. 18. dec. 23:03 UTC

Iegādes, apvienošanās, pārņemšana

Mitsubishi Materials: Impact on Consolidated Results for FY Ending March 2026 Likely to be Immaterial

2025. g. 18. dec. 23:02 UTC

Iegādes, apvienošanās, pārņemšana

Mitsubishi Materials: To Acquire 4,448 Common Shares, 13,771 Preferred Shares of Co.

2025. g. 18. dec. 23:00 UTC

Iegādes, apvienošanās, pārņemšana

Mitsubishi Materials: Investment to Strengthen Recovery Network in U.S.

2025. g. 18. dec. 22:59 UTC

Iegādes, apvienošanās, pārņemšana

Mitsubishi Materials: Investment to Contribute to Expanding Collection Volume of Secondary Raw Material

2025. g. 18. dec. 22:58 UTC

Iegādes, apvienošanās, pārņemšana

SpaceX Could Go Public by Merging With EchoStar. It Isn't a Crazy Idea. -- Barrons.com

2025. g. 18. dec. 22:57 UTC

Iegādes, apvienošanās, pārņemšana

Mitsubishi Materials: Elemental USA E-Waste Operates E-Waste Recycling Business in U.S.

2025. g. 18. dec. 22:56 UTC

Iegādes, apvienošanās, pārņemšana

Mitsubishi Materials: To Acquire Portion of Shares of Elemental USA E-Waste & ITAD

2025. g. 18. dec. 22:55 UTC

Peļņas

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

2025. g. 18. dec. 21:59 UTC

Peļņas

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

2025. g. 18. dec. 21:50 UTC

Tirgus saruna
Peļņas

Tech, Media & Telecom Roundup: Market Talk

2025. g. 18. dec. 21:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 18. dec. 21:35 UTC

Peļņas

FedEx's Earnings Were Strong. Cost Cuts and Shipment Volume Helped. -- Barrons.com

2025. g. 18. dec. 21:31 UTC

Peļņas

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

2025. g. 18. dec. 21:15 UTC

Peļņas

Nike 2Q Europe, Middle East & Africa Rev $3.39B >NKE

2025. g. 18. dec. 21:15 UTC

Peļņas

Nike 2Q Greater China Rev Down 17% >NKE

2025. g. 18. dec. 21:15 UTC

Peļņas

Nike 2Q EPS 53c >NKE

2025. g. 18. dec. 21:15 UTC

Peļņas

Nike 2Q Apparel Rev $3.91B >NKE

2025. g. 18. dec. 21:15 UTC

Peļņas

Nike 2Q Equipment Rev $550M >NKE

2025. g. 18. dec. 21:15 UTC

Peļņas

Nike 2Q N Amer Rev $5.63B >NKE

2025. g. 18. dec. 21:15 UTC

Peļņas

Nike 2Q Footwear Rev $7.66B >NKE

2025. g. 18. dec. 21:15 UTC

Peļņas

Nike 2Q Asia Pacific & Latin America Rev Down 4% >NKE

2025. g. 18. dec. 21:15 UTC

Peļņas

Nike 2Q Greater China Rev $1.42B >NKE

Salīdzinājums

Cenas izmaiņa

Simulations Plus Inc Prognoze

Cenas mērķis

By TipRanks

9.63% augšup

Prognoze 12 mēnešiem

Vidējais 20.5 USD  9.63%

Augstākais 25 USD

Zemākais 16 USD

Pamatojoties uz 5 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Simulations Plus Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

5 ratings

2

Pirkt

3

Turēt

0

Pārdot

Noskaņojums

By Acuity

316 / 374 Rangs Veselības aprūpe

Ziņu noskaņojums

Liecība "Lāču" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Virs vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
help-icon Live chat